Yes Re: eye catching news release. In the half year announcement buried on page 9, 'Patient responses to DMX-200 were measured using the Albumin Creatinine Ratio (ACR) reduction. Encouragingly, in the diabetic nephropathy sub-group of 10 patients, the average ACR was reduced by 35.6%. This is almost double the reduction in ACR seen in competing drug development programs by industry peers. ' IMO this could have been a headline item ! I am sure this will not be unnoticed anyway. Cheers
DXB
Price at posting:
14.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.